# US 2016/0251407 A1 · Glucose-responsive insulin conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251407 A1
- Document ID: US20160251407A1
- Status: Published application
- Kind: A1
- Application number: 15/025,912
- Filed: 2014-10-02
- Published: 2016-09-01
- Earliest claimed: 2013-10-04
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Songnian Lin; Lin Yan; Ahmet Kekec; Yuping Zhu; David N. Hunter; Pei Huo; Danqing Feng; Ravi P. Nargund; Christopher R. Moyes; Zhiqiang Zhao; Brenda Pipik; Dmitri Pissarnitski; Joseph L. Duffy; Erin Guidry
- Web page: https://patentgrep.com/patent/US20160251407A1

## CPC

- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 38/28: Insulins
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/62: Insulins
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

## Claims

### Claim at position 1

1: A conjugate comprising:
an insulin or insulin analog molecule covalently attached to at least one branched linker having a first arm and second arm,
wherein the first arm is linked to a first ligand that includes a first saccharide and the second arm is linked to a second ligand that includes a second saccharide and wherein the first saccharide is fucose and wherein the second saccharide is a mannose, glucosamine, glucose, bisaccharide, trisaccharide, tetrasaccharide, branched trisaccharide, bimannose, trimannose, tetramannose, or branched trimannose.

### Claim 2

(canceled)

### Claim at position 3 (depends on 1)

3: The conjugate of claim 1, wherein the branched linker is covalently linked to the amino acid at position A1 of the insulin or insulin analog molecule; position B1 of the insulin or insulin analog molecule; position B29 of the insulin or insulin molecule; position B28 of the insulin analog molecule; or position B3 of the insulin analog molecule.

### Claim at position 4 (depends on 1)

4: The conjugate of claim 1, wherein the insulin or insulin analog is covalently attached to a second branched linker having a first arm and second arm, wherein the first arm is linked to a third ligand that includes a third saccharide and the second arm is linked to a fourth ligand that includes a fourth saccharide.

### Claim at position 5 (depends on 4)

5: The conjugate of claim 4, wherein the second branched linker is covalently linked to the amino acid at position A1 of the insulin or insulin analog molecule; position B1 of the insulin or insulin analog molecule; position B29 of the insulin or insulin molecule; position B28 of the insulin analog molecule; or position B3 of the insulin analog molecule and which is not occupied by the first branched linker.

### Claim at position 6 (depends on 4)

6: The conjugate of claim 4, wherein the insulin or insulin analog is covalently attached to a third branched linker having a first arm and second arm, wherein the first arm is linked to a fifth ligand that includes a fifth saccharide and the second arm is linked to a sixth ligand that includes a sixth saccharide.

### Claim at position 7 (depends on 6)

7: The conjugate of claim 6, wherein the third branched linker is covalently linked to the amino acid at position A1 of the insulin or insulin analog molecule; position B1 of the insulin or insulin analog molecule; position B29 of the insulin or insulin molecule; position B28 of the insulin analog molecule; or position B3 of the insulin analog molecule and which is not occupied by the first branched linker and the second branched linker.

### Claim at position 8 (depends on 4)

8: The conjugate of claim 4, wherein the third, fourth, fifth, and sixth saccharides are each independently a fucose, mannose, glucosamine, glucose, bisaccharide, trisaccharide, tetrasaccharide, branched trisaccharide, bimannose, trimannose, tetramannose, or branched trimannose.

### Claim at position 9 (depends on 1)

9: The conjugate of claim 1, wherein the insulin or insulin analog is further covalently linked to a linear linker comprising a ligand that includes a saccharide.

### Claim at position 10 (depends on 9)

10: The conjugate of claim 9, wherein the saccharide a fucose, mannose, glucosamine, glucose, bisaccharide, trisaccharide, tetrasaccharide, branched trisaccharide, bimannose, trimannose, tetramannose, or branched trimannose.

### Claim at position 11 (depends on 1)

11: The conjugate of claim 1, wherein the insulin analog is insulin lispro, insulin glargine, insulin aspart, insulin detemir, or insulin glulisine.

### Claim at position 12 (depends on 1)

12: The conjugate of claim 1, wherein the conjugate displays a pharmacodynamic (PD) or pharmacokinetic (PK) profile that is sensitive to the serum concentration of a serum saccharide when administered to a subject in need thereof in the absence of an exogenous saccharide binding molecule.

### Claim at position 13 (depends on 12)

13: The conjugate of claim 12, wherein the serum saccharide is glucose or alpha-methylmannose.

### Claim at position 14 (depends on 1)

14: The conjugate of claim 1, wherein the conjugate binds an endogenous saccharide binding molecule at a serum glucose concentration of 60 mg/dL or less when administered to a subject in need thereof.

### Claim at position 15 (depends on 14)

15: The conjugate of claim 14, wherein the endogenous saccharide binding molecule is human mannose receptor 1.

### Claim at position 16 (depends on 1)

16: The conjugate of claim 1, wherein the conjugate has the general formula (I):
wherein:
(i) each occurrence of () represents a potential repeat within a branch of the conjugate;
(ii) each occurrence of is independently a covalent bond, a carbon atom, a heteroatom, or an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic;
(iii) each occurrence of T is independently a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted C1-30 hydrocarbon chain wherein one or more methylene units of T are optionally and independently replaced by —O—, —S—, —N(R)—, —C(O)—, —C(O)O—, —OC(O)—, —N(R)C(O)—, —C(O)N(R)—, —S(O)—, —S(O)2—, —N(R)SO2—, —SO2N(R)—, a heterocyclic group, an aryl group, or a heteroaryl group;
(iv) each occurrence of R is independently hydrogen, a suitable protecting group, or an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;
(v) —B is -T-LB-X, wherein each occurrence of X is independently a ligand comprising a saccharide and each occurrence of LB is independently a covalent bond or a group derived from the covalent conjugation of a T with an X; and,
(vi) n is 1, 2, or 3,
with the proviso that at least one X is fucose.

### Claim at position 17 (depends on 1)

17: The conjugate of claim 1, wherein the conjugate comprises the general formula (II):
wherein:
(i) each occurrence of () represents a potential repeat within a branch of the conjugate;
(ii) each occurrence of is independently a covalent bond, a carbon atom, a heteroatom, or an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic;
(iii) each occurrence of T is independently a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted C1-30 hydrocarbon chain wherein one or more methylene units of T are optionally and independently replaced by —O—, —S—, —N(R)—, —C(O)—, —C(O)O—, —OC(O)—, —N(R)C(O)—, —C(O)N(R)—, —S(O)—, —S(O)2-, —N(R)SO2-, —SO2N(R)—, a heterocyclic group, an aryl group, or a heteroaryl group;
(iv) each occurrence of R is independently hydrogen, a suitable protecting group, or an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;
(v) —B1 is -T-LB1-Fucose, wherein LB1 is a covalent bond or a group derived from the covalent conjugation of a T with an X;
(vi) —B2 is -T-LB2-X, wherein X is a ligand comprising a saccharide, which may be mannose, or glucose; and LB2 is a covalent bond or a group derived from the covalent conjugation of a T with an X; and,
(vii) n is 1, 2, or 3.

### Claim at position 18 (depends on 1)

18: The conjugate of claim 1, wherein the linker has formula
wherein the wavy line indicates the bond is linked to an amino acid of the insulin or insulin analog and wherein each X is independently a ligand comprising a saccharide with the proviso that at least one bi-dentate linker conjugated to the insulin or insulin analog comprises a fucose on at least one arm of the bi-dentate linker.

### Claim at position 19 (depends on 18)

19: The conjugate of claim 18, wherein each X may independently be
wherein the wavy line indicates the bond is linked to an atom comprising the bi-dentate linker.

### Claim at position 20

20-48. (canceled)

### Claim at position 21

49: A method for treating a subject who has diabetes, comprising:
administering to the subject an amount of a composition for treating the diabetes, wherein the composition comprises an insulin or insulin analog molecule conjugate covalently attached to at least one branched linker having a first arm and second arm, wherein the first arm is linked to a first ligand that includes a first saccharide and the second arm is linked to a second ligand that includes a second saccharide and wherein the first saccharide is fucose and wherein the second saccharide is a mannose, glucosamine, glucose, bisaccharide, trisaccharide, tetrasaccharide, branched trisaccharide, bimannose, trimannose, tetramannose, or branched trimannose, and a pharmaceutically acceptable carrier; wherein said administering treats the diabetes.

### Claim 50

(canceled)

### Claim at position 23 (depends on 49)

51: The method of claim 49, wherein the branched linker is covalently linked to the amino acid at position A1 of the insulin or insulin analog molecule; position B1 of the insulin or insulin analog molecule; position B29 of the insulin or insulin molecule; position B28 of the insulin analog molecule; or position B3 of the insulin analog molecule.

### Claim at position 24 (depends on 49)

52: The method of claim 49, wherein the insulin or insulin analog is covalently attached to a second branched linker having a first arm and second arm, wherein the first arm is linked to a third ligand that includes a third saccharide and the second arm is linked to a fourth ligand that includes a fourth saccharide.

### Claim at position 25

53-78. (canceled)
